This video file cannot be played.(Error Code: 102404)
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

The ASX is tipped to start its last day of trade for the week fairly flat, or just marginally in front.

The S&P 500 and Nasdaq dropped overnight, hindered by a slip in Tesla and Netflix after its quarterly results were released.

Tesla tumbled nearly 10 per cent as CEO Elon Musk hinted at future price cuts to electric vehicles. Taiwan Semiconductor Manufacturing Company – or TSMC – followed suit – losing five per cent – after the chipmaker’s quarterly revenue was down 13.7 per cent.

Streaming service Netflix was also down, shedding 8.4 per cent after falling short of its quarterly revenue targets, despite cracking down on password sharing.

The Dow Jones, however, rallied for a ninth straight trading session – its longest upwards run in several years. Pharmaceutical company Johnson & Johnson gained more than 6 per cent as it exceeded earnings predictions with MedTech sales and raised its full-year forecasts.

Back home and the Aussie dollar is buying 68 US cents, and 61 Euro cents.

Iron Ore is up 0.7 per cent to $115.15 a tonne, gold is down nearly half a per cent at 1969.62, crude oil is up 0.3 per cent at $79.70 a barrel and natural gas is up 1.15 per cent to $2.63.

More From The Market Online
The Market Online Video

Tuesday’s HotCopper Trends: Pancontinental price buckles, Advance hits gold | March 18, 2025

The ASX has been up 0.3% at 7,877 points.
The Market Online Video

Expert Exchange: Saul Eslake breaks down the risks of investing in the ASX

Like any investment, share market investing has a risk and reward-relationship.
A huge ship built by Austal cruises through the blue ocean.

Take two: Korea’s Hanwha hasn’t given up on grabbing Austal stake just yet

Heavyweight South Korean business conglomerate Hanwha Group is taking another swing at Austal Ltd (ASX:ASB) half a year after its last takeover play
3D image of ovarian cancer

CLEO Diagnostics kicks off IP transfer for ovarian cancer blood tests to US manufacturers

CLEO Diagnostics has commenced the 'technology transfer' process to a US-based manufacturing partner ahead of commercialisation.